Geode Capital Management
RNTX

Geode Capital Management’s Rein Therapeutics RNTX Stock Holding History

Geode Capital Management’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$763K Buy
733,139
+388,449
+113% +$470K ﹤0.01% 3446
2026
Q1 		$448K Buy
344,690
+60,135
+21% +$74.6K ﹤0.01% 3626
2025
Q4 		$330K Buy
284,555
+37,244
+15% +$51.3K ﹤0.01% 3734
2025
Q3 		$283K Buy
247,311
+1,856
+0.8% +$2.36K ﹤0.01% 3815
2025
Q2 		$344K Sell
245,455
-641
-0.3% -$1.15K ﹤0.01% 3673
2025
Q1 		$436K Buy
246,096
+4,659
+2% +$9.78K ﹤0.01% 3595
2024
Q4 		$555K Buy
241,437
+11,620
+5% +$35.2K ﹤0.01% 3567
2024
Q3 		$814K Buy
229,817
+59,370
+35% +$159K ﹤0.01% 3425
2024
Q2 		$472K Buy
170,447
+100,688
+144% +$414K ﹤0.01% 3579
2024
Q1 		$453K Buy
69,759
+12,471
+22% +$59.7K ﹤0.01% 3656
2023
Q4 		$174K Buy
57,288
+775
+1% +$1.51K ﹤0.01% 3989
2023
Q3 		$85.3K Buy
56,513
+1,467
+3% +$2.49K ﹤0.01% 4301
2023
Q2 		$98.5K Buy
55,046
+247
+0.5% +$380 ﹤0.01% 4338
2023
Q1 		$68.5K Buy
54,799
+10,311
+23% +$22.1K ﹤0.01% 4448
2022
Q4 		$105K Buy
44,488
+167
+0.4% +$561 ﹤0.01% 4384
2022
Q3 		$183K Buy
44,321
+668
+2% +$2.82K ﹤0.01% 4265
2022
Q2 		$226K Buy
43,653
+264
+0.6% +$2.42K ﹤0.01% 4188
2022
Q1 		$444K Buy
43,389
+289
+0.7% +$2.62K ﹤0.01% 3993
2021
Q4 		$485K Buy
43,100
+1,953
+5% +$30.2K ﹤0.01% 4063
2021
Q3 		$839K Buy
41,147
+2,806
+7% +$61.5K ﹤0.01% 3780
2021
Q2 		$958K Buy
38,341
+9,754
+34% +$243K ﹤0.01% 3627
2021
Q1 		$817K Buy
28,587
+17,121
+149% +$587K ﹤0.01% 3642
2020
Q4 		$238K Buy
11,466
+4,071
+55% +$102K ﹤0.01% 3834
2020
Q3 		$190K Buy
7,395
+306
+4% +$7.2K ﹤0.01% 3734
2020
Q2 		$167K Buy
7,089
+1,555
+28% +$25.3K ﹤0.01% 3705
2020
Q1 		$36K Buy
5,534
+939
+20% +$11.3K ﹤0.01% 3973
2019
Q4 		$52K Buy
4,595
+1,845
+67% +$18.2K ﹤0.01% 4081
2019
Q3 		$36K Hold
2,750
– – ﹤0.01% 4097
2019
Q2 		$39K Buy
2,750
+353
+15% +$9.26K ﹤0.01% 4105
2019
Q1 		$93K Buy
+2,397
New +$74.7K ﹤0.01% 3911
2018
Q2 		– Sell
-896
Closed -$145K – 4102
2018
Q1 		$145K Buy
896
+132
+17% +$23.5K ﹤0.01% 3768
2017
Q4 		$161K Sell
764
-107
-12% -$25.6K ﹤0.01% 3723
2017
Q3 		$233K Buy
+871
New +$218K ﹤0.01% 3622

Other funds holding RNTX

VC
Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
SM
Senvest Management New York $3.41B AUM 66.27% 1-Year Est. Return

Geode Capital Management's RNTX Position: Q2 2026 in Review

Geode Capital Management increased its Rein Therapeutics (RNTX) stake by 113% in Q2 2026, buying an estimated $470K and bringing the position to 733,139 shares worth $763K. The position accounts for ﹤0.01% of the portfolio, ranked #3446.

Geode Capital Management first reported a position in RNTX in Q3 2017 and has held it in 33 quarters since. The position peaked at $958K in Q2 2021. 60 funds tracked by Wall St. Rank hold RNTX as of Q2 2026.

  • Geode Capital Management held 733,139 shares of Rein Therapeutics worth $763K as of Q2 2026.
  • Geode Capital Management bought 388,449 Rein Therapeutics shares in Q2 2026, an estimated $470K.
  • Rein Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #3446 holding.
  • Geode Capital Management first reported a position in Rein Therapeutics in Q3 2017 and has held it in 33 quarters since.
  • Geode Capital Management's Rein Therapeutics position peaked at $958K in Q2 2021.
  • 60 funds tracked by Wall St. Rank held Rein Therapeutics as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.